XML 50 R39.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaboration and Licensing Agreements (Details) |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 04, 2020 USD ($) shares | Mar. 29, 2019 USD ($) | Mar. 08, 2019 | Dec. 31, 2020 USD ($) shares | Nov. 30, 2020 USD ($) item | Aug. 31, 2020 USD ($) item | Jul. 31, 2020 USD ($) Program | Feb. 29, 2020 USD ($) | Jan. 31, 2020 USD ($) item | Jun. 30, 2019 USD ($) | Feb. 28, 2019 | Oct. 31, 2017 USD ($) shares | Jan. 31, 2013 Program | Mar. 31, 2021 USD ($) item | Dec. 31, 2020 USD ($) | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) item | Dec. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | May 31, 2018 USD ($)
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other income |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,970,000 |  | $ (2,336,000) |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 77,800,000 |  | 46,200,000 |  |  |  |
Receivable |  |  |  | $ 11,443,000 |  |  |  |  |  |  |  |  |  | $ 12,525,000 | $ 11,443,000 |  |  | $ 11,443,000 |  |
Atreca, Inc. | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |
Sharing percent of costs and profits |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
License, Development, and Commercialization Agreement | Aimmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  | 9,600,000 |  |  |  |
Shares received in noncash transaction | shares | 156,238 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase amount of share options or equity in noncash transaction | $ 4,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
License, Development, and Commercialization Agreement | Aimmune | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment | 385,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option and License Agreement | Alexion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  |  |  |  |  |
Number of different target programs | Program |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |
Option and License Agreement | Alexion | Royalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,300,000 |  | 3,300,000 |  |  |  |
Option and License Agreement | Alexion | Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract asset |  |  |  | 10,000,000.0 |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |  | 10,000,000.0 |  |
Research and License Agreement | Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Research and License Agreement | Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  | 240,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 300,000 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Research and License Agreement | Astellas | Bispecific |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  | $ 13,600,000 |  |  |  |  |  |  |  |  |  |
Research and License Agreement | Astellas | Research service |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation |  | 1,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreement | Astellas | Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract asset |  |  |  | 2,500,000 |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  | 2,500,000 |  |
Research and License Agreement | Vir |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 155,000,000.0 |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Number of different target programs | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
Collaboration and License Agreement | Atreca, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs | Program |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of different target programs | Program |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement | Genentech |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial cost-sharing percentage |  |  | 45.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 |  | 700,000 |  |  |  |
Collaboration and License Agreement | Genentech | XmAb24306 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost sharing receivable (payable) |  |  |  |  |  |  |  |  |  |  |  |  |  | (2,900,000) |  |  |  |  |  |
Collaboration and License Agreement | Genentech | Research service |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,300,000 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,300,000 |  |  |  |  |  |
Collaboration and License Agreement | Genentech | Licensing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 111,700,000 |
Collaboration and License Agreement | Janssen Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation |  |  |  |  | $ 50,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  | 50,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | 662,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,600,000 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 35,400,000 |  |  |  |  |  |
Collaboration and License Agreement | MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Contract asset |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Collaboration and License Agreement | MorphoSys | Royalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,400,000 |  |  |  |  |  |
Receivable |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,400,000 |  |  |  |  |  |
Collaboration and License Agreement | MorphoSys | Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  | 12,500,000 |  | 12,500,000 |  |  |  |
Collaboration and License Agreement | Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,100,000 |  |  |  |  |  |
Cost sharing receivable (payable) |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 900,000 |  |  |  |  |  |
Collaboration and License Agreement | Novartis | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | item |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Technology License Agreement | Quellis | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 66,000,000.0
Technology License Agreement | Catabasis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other income |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,900,000 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Technology License Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  | $ 6,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  | $ 67,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 6,000,000.0 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Number of compounds | item |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Technology License Agreement | MiRagen/Viridian |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | $ 55,000,000.0 |  |  |  |  |  |  |  |  |  |  | 55,000,000.0 |  |  | 55,000,000.0 |  |
Other income |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  | 6,000,000.0 |  |
Shares received in noncash transaction | shares |  |  |  | 322,407 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase amount of share options or equity in noncash transaction |  |  |  | $ 6,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Technology License Agreement | Omeros |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  | $ 65,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Number of additional antibodies | item |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement | INmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |
Shares received in noncash transaction | shares |  |  |  |  |  |  |  |  |  |  |  | 1,585,000 |  |  |  |  |  |  |  |
Purchase amount of share options or equity in noncash transaction |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | $ 0 |  |  |  |
Option term |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |
License Agreement | INmune | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity interests (as a percentage) |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |
License Agreement | Zenas Bio Pharma Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation |  |  |  |  | 16,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Purchase amount of share options or equity in noncash transaction |  |  |  |  | $ 16,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |
Percentage of equity of private company |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of drug candidates | item |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement | Zenas Bio Pharma Limited | Licensing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,100,000 |  |  |  |  |
Development-based | License, Development, and Commercialization Agreement | Aimmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment | 22,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development-based | Research and License Agreement | Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  | 32,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development-based | Research and License Agreement | Vir |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |
Development-based | Collaboration and License Agreement | Janssen Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | $ 161,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development-based | Collaboration and License Agreement | MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract asset |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,500,000 |  |  |  |  |  |
Development-based | Technology License Agreement | Quellis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000.0
Development-based | Technology License Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Development-based | Technology License Agreement | MiRagen/Viridian |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | 10,000,000.0 |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |  | 10,000,000.0 |  |
Development-based | Technology License Agreement | Omeros |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory-based | License, Development, and Commercialization Agreement | Aimmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment | 53,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory-based | Research and License Agreement | Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  | 57,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory-based | Research and License Agreement | Vir |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |
Regulatory-based | Collaboration and License Agreement | Janssen Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | 240,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory-based | Technology License Agreement | Quellis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000.0
Regulatory-based | Technology License Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  | 27,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Regulatory-based | Technology License Agreement | MiRagen/Viridian |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |  | 20,000,000.0 |  |
Regulatory-based | Technology License Agreement | Omeros |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  | 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based | License, Development, and Commercialization Agreement | Aimmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment | $ 310,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based | Research and License Agreement | Astellas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  | $ 150,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based | Research and License Agreement | Vir |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 120,000,000.0 |  |  |
Sales-based | Collaboration and License Agreement | Janssen Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | $ 260,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based | Technology License Agreement | Quellis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000,000.0
Sales-based | Technology License Agreement | Gilead |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  | $ 30,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Sales-based | Technology License Agreement | MiRagen/Viridian |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  | $ 25,000,000.0 |  |
Sales-based | Technology License Agreement | Omeros |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (expense) related to nonoperating activities, classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of candidates for which bispecific drug developed. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementBispecificDrugDevelopmentNumberOfCandidates
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs under the collaborative agreements. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementNumberOfPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of performance obligations under the agreement. + References No definition available. + Details
Name: | xncr_CollaborativeAndLicensingAgreementsNumberOfPerformanceObligations
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNonrefundableUpfrontFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of additional antibodies in a collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfAdditionalAntibodies
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of compounds. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCompounds
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of different target programs under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the option term expiring after delivery of the data from a Phase 2 proof-of-concept clinical trial under a collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementOptionTermAfterDeliveryOfDataFromPhase2ProofOfConceptClinicalTrial
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of interest held in a private company. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementPercentageEquityPrivateCompany
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementReceivablePayableRelatedToCostSharingDevelopmentActivities
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the research license term under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The initial cost-sharing percentage. + References No definition available. + Details
Name: | xncr_InitialCostSharingPercentage
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount shares or share options could be purchased for in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References No definition available. + Details
Name: | xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationShareValue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares received [noncash or part noncash] for consideration of a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References No definition available. + Details
Name: | xncr_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesReceived
Namespace Prefix: | xncr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of additional equity interests available to be obtained in a license agreement. + References No definition available. + Details
Name: | xncr_PercentageOfAdditionalEquityInterests
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The sharing percent of percent of costs and profits. + References No definition available. + Details
Name: | xncr_PercentageOfCostsAndProfitsSharing
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AtrecaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseDevelopmentAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AimmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_MilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AstellasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_BispecificProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_ResearchActivityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_VirBiotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_Xmab24306ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_DiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_TechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_QuellisBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_CatabsisPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MiragenViridianMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_OmerosCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_InmuneBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |